Teva Innovative Medicine & Biosimilar Pipeline

By development stage – as of November 1, 2024

Technology Platforms:

Novel Biologics
Small Molecules
Digital Respiratory
Biosimilars

Under Regulatory Review

Biosimilar to Prolia® (denosumab)

Phase 3

Biosimilar to Entyvio® (vedolizumab) 03

Biosimilar to Eylea® (aflibercept) 03

Biosimilar to Xgeva® (denosumab)

Biosimilar to Xolair® (omalizumab)

Olanzapine LAI
(TEV-'749)
Schizophrenia

ICS/SABA
(TEV-'248)
Asthma 04

Biosimilar to Simponi® (golimumab) 03

Biosimilar to Simponi Aria® (golimumab) 03

Phase 2

Duvakitug
(TEV-'574) 02
Ulcerative Colitis, Crohn’s Disease

Emrusolmin
(TEV- '286) 01
Multiple System Atrophy

Phase 1

Anti-IL-15 (TEV-‘408)
Celiac & Vitiligo

TEV-'192
Immunology & Neuroscience

Anti-PD1-IL2 (TEV-’278)
Attenukine Oncology

Pre-clinical

TEV-‘333 05

TEV-'6000
Neuroscience

TEV-'279
Neuroscience

TEV-'287 01
Neuroscience

TEV-'285

TEV-'261

TEV-'294 03

TEV-'289

TEV-'288
Neuroscience

TEV-'292 03

TEV-'295 03

TEV-'296 03

TEV-'316 05

Novel Biologics
Small Molecules
Digital Respiratory
Biosimilars

Download a PDF version of Teva Innovative Medicine and Biosimilar Pipeline

Download PDF

Teva innovative medicine and biosimilar pipeline by development stage, excluding country / regional launches of products submitted or under review in new markets.

Pipeline is current as of November 1, 2024.

  1. Back to contents.

    In collaboration with MODAG.

  2. Back to contents.

    In collaboration with Sanofi.

  3. Back to contents.

    In collaboration with Alvotech for the U.S. market.

  4. Back to contents.

    In collaboration with Launch Therapeutics.

  5. Back to contents.

    In collaboration with mAbxience.